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Abstract
Objective: Brain amyloidosis is a key feature of Alzheimer’s disease (AD). It
also incorporates cerebrovascular amyloid b (Ab) in the form of cerebral amy-
loid angiopathy (CAA) involving neurovascular dysfunction. We have recently
shown by retrospective analysis that patients with mild cognitive impairment
receiving a vasoactive drug cilostazol, a selective inhibitor of phosphodiesterase
(PDE) III, exhibit significantly reduced cognitive decline. Here, we tested
whether cilostazol protects against the disruption of the neurovascular unit and
facilitates the arterial pulsation-driven perivascular drainage of Ab in AD/CAA.
Methods: We explored the expression of PDE III in postmortem human brain
tissue followed by a series of experiments examining the effects of cilostazol on
Ab metabolism in transgenic mice (Tg-SwDI mice) as a model of cerebrovascu-
lar b-amyloidosis, as well as cultured neurons. Results: We established that
PDE III is abnormally upregulated in cerebral blood vessels of AD and CAA
subjects and closely correlates with vascular amyloid burden. Furthermore, we
demonstrated that cilostazol treatment maintained cerebral hyperemic and va-
sodilative responses to hypercapnia and acetylcholine, suppressed degeneration
of pericytes and vascular smooth muscle cells, promoted perivascular drainage
of soluble fluorescent Ab1-40, and rescued cognitive deficits in Tg-SwDI mice.
Although cilostazol decreased endogenous Ab production in cultured neurons,
C-terminal fragment of amyloid precursor protein expression was not altered in
cilostazol-treated Tg-SwDI mice. Interpretation: The predominant action of
cilostazol on Ab metabolism is likely to facilitate Ab clearance due to the
sustained cerebrovascular function in vivo. Our findings mechanistically
demonstrate that cilostazol is a promising therapeutic approach for AD and
CAA.
ª 2014 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals, Inc on behalf of American Neurological Association.
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Introduction
Alzheimer’s disease (AD) is the most common form of
dementia. In addition to neurofibrillary tangles (NFTs),
the major pathological features in AD comprise brain
accumulation of amyloid b peptide (Ab) as senile pla-
ques and in the form of cerebral amyloid angiopathy
(CAA).1 The deposition of Ab in cerebral blood vessels
influences vascular function and worsens the pathology
contributing to cognitive decline.2–6 Recent studies sug-
gest reduced Ab clearance from the brain rather than
increased Ab production is responsible for Ab accumu-
lation in the brain in the common late-onset form of
AD.7 Ab may be degraded by glial cells,8,9 and proteases
(e.g., by neprilysin or insulin degrading enzyme)10 and
is transported across the endothelium by the low-den-
sity lipoprotein receptor-related protein 1 (LRP-1) or
the receptor for advanced glycation end products
(RAGE).11,12 The drainage of extracellular Ab along the
basement membranes of capillaries and arteries appears
as the most important mechanism for removal of Ab
from the brain.3,13,14 Besides impacting on the structural
and functional components of the neurovascular unit,
deposition of Ab within the perivascular drainage path-
way lowers the motive force of Ab clearance, thereby
contributing to increased parenchymal Ab deposi-
tion.15,16 Indeed, a recent study using real-time imaging
showed direct evidence that tracers injected into the liv-
ing mouse brain were cleared along arteries and capil-
laries but not veins.17 Solute clearance along the
perivascular route was impaired in mice with hemo-
dynamic insufficiency as well as in APPswe/PS1dE9
transgenic mice, which develop parenchymal and micro-
vascular amyloid deposits.17 Consistent with such find-
ings, immunotherapy intended to reverse the
accumulation of Ab plaques in the brain has been
shown to concomitantly increase cerebrovascular Ab
and exacerbate microvascular lesions.18,19 Unusually high
levels of soluble Ab have been also detected in the
brains of immunized AD patients.20 These results sug-
gest that Ab immunization may result in the failure of
efficient perivascular drainage of Ab solubilized from
plaques resulting in an increase in the severity of
CAA.18,21 Thus, approaches that enhance Ab clearance
via perivascular drainage and protect the neurovascular
unit hold promise for the development of novel thera-
pies for AD.
Cyclic nucleotide phosphodiesterases (PDEs) play crit-
ical roles in regulating intracellular cyclic nucleotides
(cyclic adenosine monophosphate (cAMP) and cyclic
guanosine monophosphate), which are important second
messengers involved in intracellular signal transduction
in all tissues. Thus far, 11 PDE families have been
described, most of them are expressed in the brain,
attracting attention as a source of new targets for the
treatment of psychiatric and neurodegenerative dis-
orders.22,23 PDE III, PDE IV, or PDE V inhibitors have
been shown to have positive effects on the pathology
and behavior in several animal models of AD22–25 and
human studies of AD patients.26,27 Most of these stud-
ies were based on the perspective of neuronal/synaptic
and glial dysfunction, and impairment of neurogenesis
and synaptic resilience in AD models and patients.
However, considering that vascular impairment in the
context of neurovascular unit is also closely associated
with the pathogenesis of AD/CAA28,29 and the failure of
Ab immunotherapy,18,20 restoring vascular integrity in
addition to neuronal/synaptic and glial function should
be crucial for the treatment of AD/CAA.
PDE III is the major cAMP-hydrolyzing PDE (a nega-
tive regulator of cAMP) uniquely expressed in vascular
smooth muscle cells, and PDE IIIA isoforms are also
involved in cardiovascular function by regulating vascular
smooth muscle growth regulation and phenotypic
changes. Cilostazol, a selective inhibitor of PDE III,
increases cAMP in vascular cells and has multiple effects
on the vasculature such as vasodilatation, anti-oxidation,
anti-inflammation, regulation of smooth muscle cell,30
increase in cerebral hemodynamics,31 pulse duration
time32 and arterial elasticity33 with maintenance of micro-
vascular integrity.34 We have recently shown that patients
with mild cognitive impairment receiving cilostazol exhi-
bit significantly reduced cognitive decline,35,36 suggesting
that cilostazol, originally a drug for stroke and peripheral
arterial disease, is effective for dementing disorders
through its action on the vasculature and providing ratio-
nale of experimental study using an animal model of
cerebrovascular b-amyloidosis.
Given the rationale and background outlined above,
we first explored the expression of PDE III in postmor-
tem human brains followed by a series of experiments
using transgenic mice (Tg-SwDI mice) expressing the
Swedish (K670/M671L) and vasculotropic Dutch/Iowa
(E693Q/D694N) mutant of the human amyloid precursor
protein (APP) to examine whether cilostazol protected
against the disruption of the neurovascular unit and res-
cued the perivascular drainage of Ab in AD/CAA. We
further investigated whether cilostazol is beneficial or
improves vascular reactivity, cerebral blood flow (CBF),
perivascular Ab drainage, vascular morphology, and
behavioral/cognitive function in the transgenic mice,
which exhibit deficient cerebral clearance of Ab.37 Fur-
thermore, we examined whether cilostazol can alter the
Ab biogenesis in cultured neurons as well as the in vivo
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system. These experimental approaches provide strong
rationale for placebo-controlled pharmacological trials to
establish the efficacy of cilostazol in patients with AD/CAA.
Subjects/Materials and Methods
Postmortem human brain material
Autopsied brains were obtained from Kyoto University
Hospital through a process approved by an institutional
research committee. Methods and relevant references are
available in the Data S1.
Experimental study
We used transgenic mice, C57BL/6-Tg(Thy1-APPSwDutI-
owa) BWevn/J (Jackson Laboratory, Bar Harbor, ME) as
a CAA mouse model. Experimental details are available in
the Data S1.
Results
PDE III, a negative regulator of cAMP, was
abnormally expressed in the cerebral
vessels of AD/CAA patients and correlated
with the vascular amyloid burden
On the basis that PDE III is a vasoactive enzyme uniquely
expressed in vascular smooth muscle cells and plays a piv-
otal role in vascular function, we evaluated PDE IIIA
immunoreactivity in postmortem human brains. The
demographic details and pathological findings are sum-
marized in Table S1. PDE IIIA immunostaining was neg-
ligible in the brain without CAA (Fig. 1A–C). In contrast,
PDE IIIA-immunoreactivity was upregulated mostly in
the vascular smooth muscle cells, of both the leptomenin-
geal and cortical arteries as CAA severity increased
(Fig. 1D–L and N) with a significant linear correlation
(Rs = 0.8272, P < 0.001 for Spearman’s rank correlation
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Figure 1. PDE IIIA expression is upregulated in the vascular wall in close correlation with CAA severity. (A–L and N) Representative images
of Congo red staining (A, D, G and J), Ab immunostaining (B, E, H and K), and PDE IIIA immunostaining (C, F, I, L and N) in the
leptomeningeal (left) and intracerebral cortical (right) vessels of patients without CAA (A–C) and with mild CAA (D–F), moderate CAA (G–I),
and severe CAA (J–L and N). Scale bar indicates 100 lm. (M) Histogram showing the percentage of vessels with PDE IIIA expression (none,
low, medium, and high) in patients without CAA and with mild, moderate, and severe CAA. PDE, phosphodiesterases; CAA, cerebral
amyloid angiopathy.
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coefficient, Fig. S1). Two relatively pure CAA cases (Case
No. 9 and 15; moderate and severe, respectively) showed
increased PDEIII expression, while two controls (Case
No. 16 and 17) without brain pathology showed lower
PDEIII expression score (Table S1). PDE IIIA was also
detected in the parenchyma (Fig. S2A–C). Some of the
cortical capillaries exhibited PDE IIIA immunostaining in
the vascular walls suggestive of pericytes (Fig. S2D and
E). Some of neurons including dystrophic neurites
around the amyloid core showed PDE IIIA expression
(Fig. S3E–L). However, neuropil threads and amyloid
cores did not express PDE IIIA (Fig. S3E–L). The aged
Tg-SwDI mice also showed the increased expression of
PDE IIIA in the vascular wall of the leptomeningeal and
intracortical arteries (Fig. S4). These results suggested that
PDE IIIA expression is abnormally upregulated especially
in the vascular smooth muscle cells in close correlation
with the vascular amyloid burden.
Cilostazol restored vasoreactivity in Tg-SwDI
mice
Impairments in cerebral circulation and vascular reactivity
have substantial roles in the onset and progression of AD/
CAA in human38 and mouse models of AD/CAA includ-
ing Tg-SwDI mice.5,39 Consistent with the previous
reports, which demonstrated that the Tg-SwDI mice
showed microvascular Ab deposition throughout the fore-
brain by 12 months of age,37 most of the vessels were
affected by microvascular amyloid in vehicle-treated Tg-
SwDI mice aged 23 months (Fig. S5). We first investi-
gated whether cilostazol ameliorates vascular dysfunction
in Tg-SwDI mice. Resting CBF was marginally increased
in cilostazol-treated Tg-SwDI mice compared with vehi-
cle-treated Tg-SwDI mice both aged 12 months (8-month
cilostazol treatment vs. vehicle; 26.7  1.3 vs. 25.1  1.1,
P = 0.13) and aged 15 months (13.5-month cilostazol
treatment on vs. vehicle; 27.9  2.9 vs. 26.1  3.2,
P = 0.09) (Fig. 2A–D; left panels) but these increments
did not reach statistical significance. However, cilostazol-
treated mice showed a significant increase in CBF
response to hypercapnia compared with vehicle-treated
Tg-SwDI mice both aged 12 months (8-month cilostazol
treatment vs. vehicle; 28.0  4.3% vs. 19.6  2.2%;
P = 0.0495) and aged 15 months (13.5-month cilostazol
treatment vs. vehicle; 24.3  6.1% vs. 15.5  3.9%,
P < 0.01) (Fig. 2A–D; right panels). We evaluated the va-
sodilatory response to hypercapnia and acetylcholine
using in vivo imaging (Fig. S6). We assessed the vessels
that are comparable in the baseline vascular diameters
between the treated and untreated groups (Fig. 2E and F;
left panels). However, cilostazol-treated Tg-SwDI mice
showed significant increases in the vasodilatory response
to hypercapnia (Fig. 2E and F; right panels) and acetyl-
choline both aged 12 months (8-month cilostazol treat-
ment vs. vehicle; 19.0  3.2% vs. 12.1  2.9% for
hypercapnia, P = 0.0495; 17.4  2.3% vs. 11.2  3.6%,
P = 0.0495 for acetylcholine) (Fig. 2G) and aged
15 months (13.5-month cilostazol treatment vs. vehicle;
16.3  4.5% vs. 11.5  1.1% for hypercapnia, P < 0.01;
14.7  3.2% vs. 9.3  0.8% for acetylcholine, P = 0.032)
(Fig. 2H). This was consistent with the results of CBF
response. These findings indicated that cilostazol restores
cerebral hemodynamic reserve in Tg-SwDI mice.
Cilostazol facilitated perivascular drainage
of Ab in Tg-SwDI mice
Cerebrovascular dysfunction and reduced arterial pulsa-
tions may result in the failure of perivascular drainage of
soluble Ab, leading to the accumulation and aggregation
of Ab in the vessel walls and in the brain parenchyma.17
We investigated whether the restoration of vascular reac-
tivity by cilostazol led to an improvement of perivascular
drainage of soluble Ab in Tg-SwDI mice. Intracerebral
injections of soluble fluorescent HiLyte Ab tracers were
performed, following the methodology described before13
(Fig. 3A). Thirty minutes after the injection into the stria-
tum, soluble fluorescent Ab1-40 had spread diffusely
throughout the brain parenchyma and was present within
the basement membranes of parenchymal and leptomen-
ingeal arteries. At 30 min post-injection, most of the Ab
had drained out of the brain from the site of injection
and Ab was detected only in the leptomeningeal arteries
(Fig. 3B), and within Iba-1-positive microglia as well as
NeuN-positive neurons (data not shown). Within the
leptomeningeal arteries, Ab was located outside the platelet
endothelial cell adhesion molecule-1-positive endothelial
cells and colocalized with smooth muscle actin-positive
vascular smooth muscle cells (data not shown) and the
laminin present in the basement membranes surrounding
smooth muscle cells (Fig. 3C). The radial spread of Ab
localized in the leptomeningeal arteries from the injection
site was calculated. We did not quantify the fluorescent
Ab -positive vessels around the needle tract as they could
be technical artifacts. The number of vessels analyzed was
similar for vehicle- and cilostazol-treated Tg-SwDI mice
(cilostazol vs. vehicle; 31  3.7 vs. 29  7.0). There were
marginally significant and significant differences in the
averaged and maximal radial spread of fluorescent Ab1-40,
respectively, between vehicle- and cilostazol-treated Tg-
SwDI mice at 15 months of age (13.5-month cilostazol
treatment vs. vehicle; 2783  234 lm vs. 2395  186 lm
for average spread, P = 0.057; 3678  238 lm vs.
2820  386 lm for maximum spread, P = 0.028)
(Fig. 3D and E). These results suggest that long-term
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cilostazol treatment helps to maintain efficient perivascu-
lar drainage of Ab in Tg-SwDI mice.
Cilostazol reduced Ab deposits in the
Tg-SwDI mice brain
Tg-SwDI mice develop robust accumulation of both vas-
cular and parenchymal Ab deposits with predominance of
Ab1-40 over Ab1-42 in the perivascular/vascular areas start-
ing at 3 to 5 months of age (Fig. S7A–D).37 We hypothe-
sized that facilitation of perivascular Ab drainage with
cilostazol reduces Ab deposits. Thus, we assessed the
effects of cilostazol on Ab accumulation in the Tg-SwDI
mice brain. Cilostazol-treated Tg-SwDI mice showed sig-
nificantly or marginally significantly decreased immunore-
activity of Ab in the frontal cortex (Fig. 4A) and
hippocampus (Fig. 4B) compared with vehicle-treated
Tg-SwDI mice both aged 12 months (frontal cortex,
P = 0.0495; hippocampus, P = 0.0495) (Fig. 4C) and
15 months (frontal cortex, P = 0.057; hippocampus,
P = 0.029) (Fig. 4D). Both vehicle- and cilostazol-treated
Tg-SwDI mice did not show apparent microhemorrhage
aged 15 months (Fig. S7E and F). The evaluation of the
blood brain barrier (BBB) integrity using Evans blue also
showed that the Tg-SwDI mouse aged 10 months did not
exhibit apparent Evans blue extravasation into the central
nervous system (CNS) parenchyma; however, Evans blue
did diffuse throughout the extracellular space in non-
neural tissue (e.g., kidney, heart, and liver) (Fig. S8).
Taken together, the above results indicated that cilostazol
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Figure 2. Cilostazol-treated Tg-SwDI mice exhibit increased cerebral blood flow response to hypercapnia and increased vasodilative response to
hyperacapnia and acetylcholine. (A and B) Representative images showing temporal changes of cerebral blood flow (CBF) before (Pre) and after
(Post) hypercapnia in vehicle-treated and cilostazol-treated Tg-SwDI mice. (C) Histogram showing CBF (left) and % increase in CBF (right) in
vehicle-treated (n = 3) and cilostazol-treated (n = 3) Tg-SwDI mice aged 12 months treated from aged 4 months. (D) Histogram showing CBF
(left) and % increase in CBF (right) in vehicle-treated (n = 7) and cilostazol-treated (n = 9) Tg-SwDI mice aged 15 months treated from aged
1.5 months. Error bars indicate SD. **P < 0.01 and *P < 0.05 in vehicle-treated Tg-SwDI mice versus cilostazol-treated Tg-SwDI mice. (E and F)
Representative images showing temporal changes of leptomeningeal arteries before (left) and after (right) hypercapnia in vehicle-treated (E) and
cilostazol-treated (F) mice. Scale bars indicate 50 lm. (G) Histogram showing % increase of vascular diameter in response to hypercapnia (left)
and acetylcholine (ACh, right) in vehicle-treated (n = 3) and cilostazol-treated (n = 3) Tg-SwDI mice aged 12 months treated from aged
4 months. (H) Histograms showing % increase of vascular diameter in response to hypercapnia (left) and acetylcholine (right) in vehicle-treated
(n = 4) and cilostazol-treated (n = 5) Tg-SwDI mice aged 15 months treated from 1.5 months. Error bars indicate SD. *P < 0.05 in vehicle-treated
Tg-SwDI mice versus cilostazol-treated Tg-SwDI mice.
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reduces Ab accumulation in the Tg-SwDI mice brain pos-
sibly by promoting perivascular drainage of Ab associated
with preserved hemodynamic reserve.
Cilostazol attenuated the degradation of
vascular walls with Ab deposit
To examine the nature of Ab accumulation and morpho-
logical changes in detail, we performed electron micros-
copy of Tg-SwDI mice aged 21 months that had been
treated with cilostazol or vehicle for 17 months. Whereas
25% (49 per 195) of the vessels in the vehicle-treated Tg-
SwDI mice showed some type of abnormality in the vas-
cular wall vis-a-vis degeneration of pericytes or vascular
smooth muscle cells or damaged intracellular organelles
and alterations in the basement membranes (Fig. 5A–C,
and Fig. S9A–D), only 6.4% (10 vessels per 155) of the
vessels was affected in the cilostazol-treated mice
(Fig. 5D–F, and Fig. S9E and F). The majority of degen-
erating pericytes in vehicle-treated Tg-SwDI mice exhib-
ited morphological changes related to severe cell injury.
These were apparent as numerous large vesicles, mem-
branes around portions of the cytoplasm (called isolation
membrane), mitochondrial injury, lysosomal inclusions,
and large lysosomes were found in the cytoplasm of peri-
cytes, mostly markers of autophagy (Fig. 5A, and Fig.
S9A and B). The arterioles of vehicle-treated Tg-SwDI
mice showed a similar degeneration of vascular smooth
muscle cells with vacuolization and destroyed organelles
accompanied by basement membrane thickening/altera-
tions (Fig. 5B, C, and Fig. S9C, D). Conversely,
cilostazol-treated Tg-SwDI mice only rarely showed the
above-abnormal findings (Fig. 5D–F, and Fig. S9E and F).
Cilostazol prevented the decline of
cognitive and grooming performance in
Tg-SwDI mice
To evaluate cognitive function, we examined behavioral
performance by using the Y maze test. Alternations of
entries in the arms of the Y maze were significantly
increased in cilostazol-treated Tg-SwDI mice (67.0  2.9%)
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compared with vehicle-treated mice (54.9  3.3%) aged
12 months (P < 0.001; Fig. 6A, right panel). Spontaneous
activity was not significantly different between the two
groups of mice (Fig. 6A, left panel). At 15 months of age,
although there was a trend for increase in alternations of
entries in cilostazol-treated mice, no significant difference
in both alternations of entries in the arms and spontane-
ous activity between vehicle- and cilostazol-treated Tg-
SwDI mice (Fig. 6B). There were no significant differ-
ences in the number of total entries and alternations of
entries between vehicle- and cilostazol-treated wild type
mice aged 12 months (Fig. S10). Cilostazol-treated Tg-
SwDI mice showed significantly better hair condition
compared with vehicle-treated Tg-SwDI mice aged
15 months, also suggesting that cilostazol prevents cogni-
tive decline in Tg-SwDI mice (Data S1 and Fig. S11).
Cilostazol suppressed endogenous Ab
production in the primary cultured neurons
There is a possibility that the observed reduction in Ab
deposition is a consequence of decreased Ab production,
in addition to increased Ab clearance. Indeed, a previous
study showed that cilostazol decreased extracellular and
intracellular Ab levels in mouse neuroblastoma N2a cells
expressing human APP with Swedish mutation.25 We
examined the effect of cilostazol on endogenous Ab pro-
duction from neurons in vitro using the primary cultured
rat neurons. This showed that cilostazol decreased the
amount of Ab40 and Ab42 in the media released from
neurons in a dose-dependent manner (Fig. 7A and B). A
WST assay showed no significant differences among these
groups (Fig. 7C). These results suggest that cilostazol can
suppress the endogenous Ab production from neurons
without affecting cell viability.
Cilostazol did not affect APP processing in
Tg-SwDI mice
Although cilostazol does reduce neuronal Ab production,
it has been established that only a very minor fraction of
cilostazol can cross BBB and enter the brain after the
peroral administration.40 Therefore, the direct effects of
cilostazol on neurons were expected to be less significant
in vivo than in vitro. Based on the knowledge that b-sec-
retase activity is augmented by hypoperfusion,41 which
may be ameliorated with cilostazol administration, we
performed quantitative immunoblotting using antibody
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against APP C-terminal domain, as a marker of APP pro-
cessing. There were no significant differences in the levels
of APP and APP C-terminal fragments (CTFs) between
vehicle- and cilostazol-treated Tg-SwDI mice aged
15 months, which had received vehicle or cilostazol for
13.5 months (Fig. 8).
Discussion
The complex expression patterns and activity of the dif-
ferent PDEs throughout the CNS under normal and path-
ological conditions have been the subject of intense
interest during the past decade, especially in regard to the
therapeutic potential of PDE inhibitors for CNS disor-
ders.22,23 We found that PDE IIIA expression in the
microvessels, predominantly in the smooth muscle cell
layers, was markedly upregulated as CAA severity
increased. To our knowledge, this is a first report showing
the upregulation of PDE IIIA expression in the microves-
sels in close correlation with vascular amyloid burden.
Further studies, including in vitro studies, are needed to
clarify whether the increased PDE IIIA expression is a
cause or consequence of amyloid deposit.
Our experimental study demonstrated that cilostazol,
PDE III inhibitor, restores vascular reactivity and hemo-
dynamic reserve, promotes perivascular drainage of Ab,
reduces degenerative changes of vascular walls with Ab
deposits and prevents the decline of cognitive perfor-
mance in the Tg-SwDI mice, a model for cerebrovascular
b-amyloidosis. These protective roles of cilostazol against
Ab-induced neurodegeneration seem to be mediated by
its vasculotropic, but not antiplatelet, effects, as long-term
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Figure 5. Electron microscopic images of vehicle-treated (A–C) and cilostazol-treated (D–F) Tg-SwDI mouse aged 21 months. The vehicle-treated
Tg-SwDI mice showed marked degenerative changes of cerebral vessels, which were suppressed by long-term cilostazol treatment. (A) Numerous
large vesicles and empty space were present in the cytoplasm of pericytes (*). Inset: Higher magnification of multiple vesicles (dashed square). The
arrow indicates isolation membrane. (B) Degenerative changes of smooth muscle cells (+) accompanied with thickening/alterations of basement
membrane (arrows) and amyloid fibril deposit (++). (C) Endothelial degeneration indicated by damaged intracellular organelles, replaced by dark
materials (arrows). (D) Mild degenerative changes of pericyte were seen. Small vacuoles and dark materials in the cytoplasm of pericyte were
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aspirin treatment did not reverse vascular Ab deposition,
hemodynamic derangements, or cognitive decline in
Tg-SwDI mice (unpublished data). Thus, besides its anti-
platelet actions, the maintenance of neurovascular integ-
rity with cilostazol could represent a promising approach
in the decelerating cognitive decline associated with Ab
deposition. Since the motive force for perivascular Ab
drainage appears to be generated by arterial pulsa-
tions,42,43 the direct action of cilostazol on the vascular
smooth muscle cells to increase pulse duration time32 and
arterial elasticity33 may have contributed to the facilitated
perivascular drainage of Ab and the above positive effects
of cilostazol in the Tg-SwDI mice. Furthermore, as elec-
tron microscopic examinations have revealed, the protec-
tion of pericytes and other vascular components by
cilostazol may have led to the preservation of vasodilative
and hemodynamic reactivity and BBB integrity along the
perivascular drainage pathway.
The CNS is devoid of conventional lymphatic vessels,
unlike other organs that contain networks of lymphatic
vessels, which process various elements such as wastes,
fluid, proteins, and cells from tissues to lymph nodes.15,42
However, the perivascular drainage system in the brain
performs the main function assigned to systemic lympha-
tic vessels.13–15,42,44 Animal studies using various tracers
have demonstrated that interstitial fluid and solutes drain
rapidly via perivascular “lymphatic” pathways from brain
parenchyma along basement membranes in the walls of
capillaries and arteries in the opposite direction of the
arterial blood flow to cervical lymph nodes.15,17,42 This
drainage route corresponds very closely with the distribu-
tion of Ab in the basement membranes of capillary and
artery walls in CAA.45 The failure of this drainage in the
ageing brain and in the presence of CAA results in the
accumulation of insoluble and soluble Ab and probably
other metabolites that would lead to loss of homeostasis
of the neuronal environment.15,42 This notion is also sup-
ported by the experimental data that the vascular Ab
deposition is increased following bilateral common caro-
tid artery stenosis of CAA model mice46 or middle cere-
bral artery occlusion model mice.47 Such “lymphatic”
congestion of the brain may be improved by vasoactive
cilostazol.
Nevertheless, there is a possibility that the observed
reduction in Ab deposition could largely be a conse-
quence of decreased Ab production, rather than increased
Ab clearance. According to previous studies, cilostazol
could regulate APP processing via the cAMP-PKA path-
way or activation of CREB cascade,26 and PKA has been
implicated in the regulation of APP processing.48 In addi-
tion, the PDE V inhibitor sildenafil has been shown to
reduce brain Ab through the cGMP-CREB pathway.49
Given that the activation of the 5-HT4 receptor could
regulate a-secretase activity, which is associated with
cAMP functional response,50 cilostazol-mediated cAMP
might enhance a-secretase activity, leading to decreased
Ab production. Indeed, the current study showed that cil-
ostazol could decrease endogenous Ab generation from
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the cultured neurons in vitro. There is also a possibility
that the improvement of cerebral hemodynamics by cil-
ostazol could reduce in Ab synthesis as hypoxia/hypoper-
fusion has been shown to upregulate b-secretase
BACE1.41 However, cilostazol did not alter the levels of
APP CTFs in Tg-SwDI mice in vivo. This discrepancy
could be attributed to the poor ability of cilostazol to
cross the BBB,40 as well as the finding that BBB was not
apparently disrupted in middle-aged Tg-SwDI mice in the
current study. It is nonetheless possible that cilostazol,
even at a low level, activates cAMP-PKA signaling with a
similar mechanism to enriched environment, leading to
the activation of b2-adrenergic receptors and inhibition
of synaptotoxicity of human Ab oligomers.51 Taken
together, the positive effects of cilostazol in vivo observed
in the current study may predominantly result from facil-
itated Ab clearance due to the sustained cerebrovascular
function; however, the previously unidentified mecha-
nisms leading to Ab reduction, could offer a potential
source of future investigation.
The use of Tg-SwDI mice has two distinctive advanta-
ges, when compared to other types of Tg mice harboring
mutant APP. Firstly, Tg-SwDI mice have been shown to
express mutant human APP at low levels, even below
those of endogenous mouse APP in the brain. Despite the
low expression levels of mutant APP, Tg-SwDI mice
develop early-onset robust accumulation of Ab in the
brain. This could result from the deficient clearance of
Dutch/Iowa mutant Ab from the CNS at the cerebral vas-
culature, as shown in the previous studies.37,52 Since
decreased elimination, rather than increased production,
of Ab is likely to be a major cause of sporadic late-onset
AD, this model would be useful for investigating the
mechanisms and therapeutic approaches for sporadic AD.
Second, Dutch/Iowa mutant Ab peptides have highly vas-
culotropic nature and Tg-SwDI mice exhibit extensive
microvascular amyloid deposition. A recent report
showed that Tg-SwDI mice, which dominantly develop
microvascular amyloid exhibit cognitive dysfunction at
3 months of age. However, Tg-5 9 FAD mice that domi-
nantly develop parenchymal amyloid deposits did not
exhibit cognitive dysfunction at this age. These findings
suggest that cerebral microvascular pathology might con-
tribute to the early stages of cognitive impairment in AD
and related disorders,53 consistent with the notion that
cerebral vascular dysfunction is an early contributor for
AD pathophysiology.2 The positive effects of cilostazol on
Tg-SwDI mice in the current study suggest that cilostazol
is a promising therapeutic target for early stages of cogni-
tive impairment of neurodegenative etiology.
There are several issues to be addressed in future
studies. First, we focused on only middle-aged and old
Tg-SwDI mice, although emerging evidence shows that
early vascular changes may precede Ab accumulation and
progressive disease cascades. Further studies are needed to
elucidate whether cilostazol can improve early vascular
alterations in young Tg-SwDI mice. Second, we specifi-
cally focused on perivascular drainage of Ab. However,
other clearance mechanisms, such as transcytotic delivery
across BBB or degradation of Ab by microglial/astroglial
cells or enzymes, might contribute to reduction of Ab
overload. In addition, clearance pathways other than peri-
vascular lymphatic routes, such as paravenous routes and
bulk fluid flow through astrocytic endfeet54 or paraaxo-
nal/neuronal pathways, should be considered in future
studies. Finally, the current study shows that cilostazol
reduces Ab overload by hemodynamic enhancement.
However, the accumulation of NFTs within neurons,
composed largely of ubiquitin and the microtubule-asso-
ciated protein tau, is another important hallmark of AD.1
While the accumulation of Ab may derive mainly from
the failure of the clearance system as mentioned above,
that of NFTs appears to be associated at least partially
with the failure of the ubiquitin-proteasome system.16
Additionally, hemodynamic insufficiency has been shown
to enhance phosphorylation of tau through upregulation
of tau phosphorylating enzymes.55 Further studies are
warranted to examine whether cilostazol have positive
effects on the neuropathology of NFTs as well as Ab.
In conclusion, our study showed that the vasoactive
drug cilostazol, a PDE III inhibitor, prevented cognitive
decline triggered with Ab deposition by facilitating Ab
clearance out of the brain and preserving neurovascular
unit. Cilostazol, which can resolve the failure of the Ab
drainage pathway may provide a novel promising thera-
peutic target for AD/CAA, potentially in combination
with early Ab immunization therapy and pharmacological
intervention to enhance enzymatic degradation of Ab and
absorption of Ab into the blood. A prospective trial is
now needed to determine the effects of cilostazol on AD/
CAA.
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Figure S1. The correlation between the CAA severity and
the PDE IIIA expression score demonstrates significant
linear correlation (Rs = 0.8272, P < 0.001). PDE IIIA
expression score was calculated from the average of quali-
fied grading of PDE IIIA expression (0 = none, 1 = low,
2 = medium, 3 = high).
Figure S2. (A–E) Representative images of PDE IIIA im-
munostaining in patients with AD and CAA. PDE IIIA
expression is only slightly observed in neurites in the
cerebral cortex (A) and pyramidal neurons in the hippo-
campal CA3 regions (B) and dentate gyrus (C), whereas it
is strong in the cortical vessels in patients with AD/CAA
(D, E). Scale bar indicates 50 lm.
Figure S3. Representative images of the leptomeningeal
arteries (A–D), the cerebral cortex (E–H), and the senile
plaques (I–L), which were stained for Ab (A, E, I), paired
helical filament-tau (PHF-tau) (B, F, J), PDE IIIA (C, G,
K), and Congo red (D, H, L) in patients with AD and
CAA. Of note, some neurons with dystrophic neurites (J,
dashed arrow) showed PDE IIIA expression (G, K), but
neuropil threads (F, arrows) and amyloid cores (I and L,
arrows) were not positive for PDE IIIA. Scale bar indi-
cates 50 lm.
Figure S4. PDE IIIA expression is increased in the vascu-
lar wall in aged Tg-SwDI mouse. Representative images of
PDE IIIA immnostaining in the leptomeningeal (A–C)
and intracortical (D–F) arteries of wild type mouse aged
12 months (A and D), Tg-SwDI mouse aged 4 months
(B, E), and Tg-SwDI mouse aged 23 months (C and F).
Scale bar indicates 20 lm.
Figure S5. Thioflavin-S staining in the Tg-SwDI mouse
aged 23 months. Scale bars indicate 100 lm in A–F,
1 mm in G, and 500 lm in H and I.
Figure S6. Representative images of vehicle- (A) and cil-
ostazol-treated (B) Tg-SwDI mice showing where vessel
diameter was quantified. An averaged vessel diameter
across a 25 lm longitudinal segment (8 consecutive seg-
ments per mouse) was analyzed before (baseline) and
after inhalation of 5% CO2 or treatment with acetylcho-
line. Scale bars indicate 50 lm.
Figure S7. Tg-SwDI mice exhibit robust accumulation
of both vascular and parenchymal Ab with predomi-
nance of Ab40 over Ab42 in the perivascular/vascular
areas without apparent microhemorrhage or BBB leak-
age at 15 months of age. (A–D) Representative images
of Ab40 (A), Ab42 (B), and Ab (6E10) immunostaining
(C and D), Perls-Stieda’s iron staining (E), and IgG
staining (F) in Tg-SwDI mice aged 15 months. Scale
bars indicate 50 lm in A and B, 20 lm in C and D,
and 100 lm in E and F.
Figure S8. Representative macroscopic (A and B) and
microscopic fluorescent (C and D) images of the brain
(A, C) and kidney (B and D) in the Tg-SwDI mouse
aged 10 months after Evans blue, followed by FITC
dextran (green), injection. There were clear differences
in the extravascular extravasation of Evans blue (shown
in blue in A, B, and red in C, D) between the brain
and kidney. Scale bars indicate 50 lm.
Figure S9. Electron microscopic images of vehicle-trea-
ted (A–D) and cilostazol-treated (E, F) Tg-SwDI mice
aged 21 months. (A) Multiple vesicles in the cytoplasm
of pericytes. (B) Multiple vesicles (+) and damaged
intracellular organelles including mitochondria replaced
by dark material (upper inset) in the pericytic cyto-
plasm. Multiple vacuoles (++) and thickening/alterations
of basement membrane (lower inset). The regions
marked by dashed squares are enlarged in the right
upper and lower inset, respectively. (C) Thickening/
alterations of basement membrane. The region marked
by a dashed square is enlarged in the inset. (D) Two
transversely sectioned microvessels were seen connected
by a dysmorphic process. Multiple stages of autosomes,
lysosomes, and damaged intracellular organelles with
disruption of mitochondrial membrane and reduced
cristae (arrows, right lower inset) were present (++).
The regions marked by dashed squares are enlarged in
the right upper and lower inset, respectively. (E and F)
Almost intact capillaries were seen in cilostazol-treated
Tg-SwDI mice. Arrows indicate tight junction of endo-
thelial cells. Pericytic mitochondria were normal. The
region marked by a dashed square is enlarged (F, inset).
Scale bars indicate 1 lm. As, astrocyte; Ax, axon; BM,
basement membrane; E, endothelial cell; En, nucleus of
endothelial cell; Ly, lysosome; m, mitochondrion; P,
532 ª 2014 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals, Inc on behalf of American Neurological Association.
Role of Phosphodiesterase III on Ab Drainage T. Maki et al.
pericyte; Pn, nucleus of pericyte.
Figure S10. (A) Histograms showing number of arm
entries (left) and alternation behavior (right) in the Y
maze test of vehicle-treated (n = 10) and cilostazol-trea-
ted (n = 10) wild type mice aged 12 months treated
from 11 months of age. Error bars indicate SD.
Figure S11. Grooming performance in vehicle-treated
and cilostazol-treated Tg-SwDI mice. (A) Images show-
ing the hair (ruffled coat) conditions graded as four
categories 0–3. (B) Histogram showing grading score of
the hair (ruffled coat) condition of vehicle-treated
(n = 10) and cilostazol-treated (n = 12) Tg-SwDI mice
aged 15 months. Error bars indicate SEM. *P < 0.05 in
vehicle-treated Tg-SwDI mice versus cilostazol-treated
Tg-SwDI mice.
Table S1. Detailed neuropathological features and analy-
ses of 17 patients with AD or non-AD. These patients
were also divided into 4 groups according to the Von-
sattel grade of CAA (4 patients without CAA, 4 patients
each with mild or moderate, and 5 patients with severe
CAA). The grading score of PDE IIIA expression is cal-
culated from the average of qualified grade (0 = none,
1 = low, 2 = medium, 3 = high). In total, 1700 lepto-
meningeal and cortical arteries (100 per patient) were
analyzed in the randomly selected 5 regions (20 vessels
per one region) from the temporal and occipital lobes.
AD, Alzheimer’s disease; ALS, amyotrophic lateral scle-
rosis; CAA, cerebral amyloid angiopathy; CERAD, Con-
sortium to Establish a Registry for Alzheimer’s Disease;
CHF, congestive heart failure; CLL, Chronic lympho-
cytic leukemia; NFT, neurofibrillary tangle; SIVD, sub-
cortical ischemic vascular dementia; VaD, vascular
dementia; ND, not determined.
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